US President Trump touts success of psychedelic drugs following EO signed in April, specifically Ibogaine (PBM)
Trump's announcement of receiving the 1994 Ibogaine IND accelerates regulatory approval and de-risks the sector, positioning Psyence Biomedical (PBM) as a critical GMP-certified supplier for new veteran-focused treatments.
News detail
Full Post: "In April, I signed a very important Executive Order to accelerate medical treatments for serious mental illness — Specifically, psychedelic drugs, including IBOGAINE. This is something that has helped so many of our amazing VETERANS and true American Heroes who were here in the Oval Office with me, and Joe Rogan. Today I am announcing that Secretary Kennedy has received a Historic Gift from the University of Miami, who has given the Federal Government its original 1994 Ibogaine Investigational New Drug application. This will give everyone direct access to the foundational FDA authorization to accelerate its development as a medical treatment in the U.S. This is HUGE! Special THANK YOU to the University of Miami, who has done this to ensure that Americans are helped as quickly as possible. This adds to the INCREDIBLE PROGRESS since April, including huge amounts of HHS research funding, collaboration between HHS and VA, FDA guidance, and more. We are moving FAST, so that our Veterans with serious mental illness have a RIGHT TO TRY here in the U.S. We hope to see more companies and institutions join us in this very important work. Our Veterans DESERVE it! Thank you for your attention to this matter. President DONALD J. TRUMP"
What do investors think?
StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.
